Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

Ukrainian Men Plead Guilty to Conspiracy and Trafficking of Counterfeit Cancer and Hepatitis Drugs
FDA OCI, guilty, plea, conspiracy, trafficking, counterfeit, cancer drugs, hepatitis drugs, Maksym Nienadov, Healthy Nation, Volodymyr Nikolaienko, misbranded drugs, Keytruda, Abraxane, Epclusa, Maksim Nenadov, undercover purchase, prescription drugs, computer crime, health care fraud, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - July 22, 2020 Category: Medical Law Authors: DOJ Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression. (Source: Roche Investor Update)
Source: Roche Investor Update - June 18, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - December 4, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
South San Francisco, CA -- December 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 3, 2019 Category: Drugs & Pharmacology Source Type: news

European Commission approves Roche ’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. (Source: Roche Media News)
Source: Roche Media News - September 6, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the European Commission has approved Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expressio n (≥1%) and who have not received prior chemotherapy for metastatic disease. (Source: Roche Media News)
Source: Roche Media News - August 29, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the European Commission has approved Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expressio n (≥1%) and who have not received prior chemotherapy for metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - August 29, 2019 Category: Pharmaceuticals Source Type: news

Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic no n-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - July 26, 2019 Category: Pharmaceuticals Source Type: news

Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic no n-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 26, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane®; nab-paclitaxel) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose t umours have PD-L1 expression (≥ 1%) and who have not received prior chemotherapy for metastatic disease. (Source: Roche Media News)
Source: Roche Media News - June 28, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane®; nab-paclitaxel) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose t umours have PD-L1 expression (≥ 1%) and who have not received prior chemotherapy for metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - June 28, 2019 Category: Pharmaceuticals Source Type: news

Patrick Soon-Shiong Sued Over'Catch and Kill' of Cancer Drug Patrick Soon-Shiong Sued Over'Catch and Kill' of Cancer Drug
Sorrento Therapeutics alleges that controversial billionaire Soon-Shiong prevented a bioequivalent of Abraxane from coming to the US market.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 9, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves 1st Immunotherapy Breast Cancer Drug
The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) received accelerated approval for triple-negative breast cancer that is locally advanced or has spread, cannot be surgically removed, and has cells that have a protein called PD-L1, CNN reported. (Source: WebMD Health)
Source: WebMD Health - March 12, 2019 Category: Consumer Health News Source Type: news

FDA Approves First Immunotherapy Drug for Breast Cancer
MONDAY, March 11, 2019 -- The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer. The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
Roche today announced US Food and Drug Administration approval of the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq ®(atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]). (Source: Roche Media News)
Source: Roche Media News - March 11, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
Roche today announced US Food and Drug Administration approval of the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq ®(atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]). (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test. (Source: Roche Media News)
Source: Roche Media News - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA Grants Genentech ’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
South San Francisco, CA -- March 8, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab) plus... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 8, 2019 Category: Drugs & Pharmacology Source Type: news

FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: World Pharma News)
Source: World Pharma News - January 21, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA accepts Roche ’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - January 17, 2019 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - January 17, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast can cer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. (Source: Roche Media News)
Source: Roche Media News - November 13, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast can cer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. (Source: Roche Investor Update)
Source: Roche Investor Update - November 13, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche today announced positive results from the Phase III IMpower130 study of Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). The analysis showed that Tecentriq plus chemotherapy help ed people live significantly longer compared to chemotherapy alone (median overall survival [OS] =18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI: 0.64–0.98; p=0.033) in the intention-to-treat wild-type (ITT-WT) populatio...
Source: Roche Media News - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche today announced positive results from the Phase III IMpower130 study of Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). The analysis showed that Tecentriq plus chemotherapy help ed people live significantly longer compared to chemotherapy alone (median overall survival [OS] =18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI: 0.64–0.98; p=0.033) in the intention-to-treat wild-type (ITT-WT) populatio...
Source: Roche Investor Update - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). (Source: Roche Media News)
Source: Roche Media News - October 20, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). (Source: Roche Investor Update)
Source: Roche Investor Update - October 20, 2018 Category: Pharmaceuticals Source Type: news

Roche reports good news in breast cancer combo trial
Roche announced that a Phase III trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
First Phase III immunotherapy study to demonstrate a statistically significant progression-free survival (PFS) improvement in intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple negative breast cancer (TNBC) populations Encouraging ... Biopharmaceuticals, Oncology Genentech, Roche Group, TECENTRIQ, atezolizumab, triple negative, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 2, 2018 Category: Pharmaceuticals Source Type: news

Abraxane (Albumin-bound Paclitaxel for Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2018 Category: Drugs & Pharmacology Source Type: news

Roche 'highly encouraged' by Tecentriq results in breast cancer
ZURICH (Reuters) - Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Phase III IMpassion130 study showed Roche ’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
Roche today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpassion130 study showed Roche ’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
Roche today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Media News)
Source: Roche Media News - June 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Investor Update)
Source: Roche Investor Update - June 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower130 study showed Roche ’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - May 29, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower130 study showed Roche ’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - May 29, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Roche ’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - March 20, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Roche ’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 20, 2018 Category: Pharmaceuticals Source Type: news

Billionaire Patrick Soon-Shiong, who just purchased the Los Angeles Times, is a controversial figure in medicine
Patrick Soon-Shiong, a respected transplant surgeon from the University of California at Los Angeles turned entrepreneur and philanthropist, first became famous for inventing an important cancer drug. His idea involved packaging a tumor-poisoning substance inside the protein albumin, which is one of the main “foods” for cancer growth. The medication, Abraxane, is now used for a wide range […]Related:Robin Williams’s suicide was followed by a sharp rise in ‘copycat’ deathsFDA ramps up warnings about kratom, calling unregulated herb an ‘opioid’Why car horns, pla...
Source: Washington Post: To Your Health - February 7, 2018 Category: Consumer Health News Source Type: news

NICE recommends Celgene ’s pancreatic cancer treatment abraxane for NHS use
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Celgene ’s nab-paclitaxel as a life-extending treatment for patients with progressive pancreatic cancer that has progressed. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

Were NHS chiefs right to deny pancreatic cancer drug?
The news in late 2015 that abraxane was being rejected by NICE on cost grounds was met with anger by patient groups as some people had survived years when they had been given months to live. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2017 Category: Consumer Health News Source Type: news